Akums Drugs
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Akums Drugs is positioned for stable growth, driven by strong operating leverage and a focus on expanding its contract development and manufacturing (CDMO) business. Recent management commentary highlights a 238bps YoY expansion in EBITDA margins to 15%, primarily fueled by robust volume growth and a recovery in API pricing. The company's strategic initiatives, including a joint venture in Zambia and an emphasis on high-margin export opportunities, are expected to contribute significantly to a projected 14.4% revenue CAGR through FY28E. Vista's financial outlook reflects this optimism, anticipating improving margins and stable revenue growth, supported by a strong balance sheet and manageable leverage. However, potential headwinds such as API pricing volatility and customer concentration risks warrant attention. The broader industry context remains favorable, with the Indian CDMO market projected to grow at a 7.7% CAGR, bolstered by global supply chain shifts. Over the next 12-24 months, key opportunities include scaling international operations and enhancing product mix, while watchpoints include geopolitical risks affecting raw material costs and the need for operational efficiencies
Why We Like This Stock
- Strong operating leverage with a 238bps YoY EBITDA margin expansion to 15%
- Strategic international expansion, particularly through the Zambia joint venture, expected to drive significant revenue growth
- Positive industry dynamics with the Indian CDMO market projected to grow at a 7.7% CAGR
Things To Watch Out For
- Ongoing volatility in API pricing could impact profitability
- High customer concentration, with the top 10 dealers accounting for 43.62% of sales, poses a risk
- Geopolitical uncertainties may affect raw material supply and costs
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,178 | 4,118 | 4,359 | 4,682 | 5,137 |
| Profit Before Tax (Cr.) | -19 | 325 | 402 | 551 | 583 |
| PBT Margin | -0.5% | 7.9% | 922.2% | 11.8% | 11.4% |
| Net Profit (Cr.) | -136 | 248 | 304 | 420 | 443 |
| Earnings Per Share | -9.2 | 15.8 | 19.8 | 27.3 | 28.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 850 | 11-Aug-2026 |
Company Overview
Show Company Profile
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.